Document Detail

Restenosis treatment in the drug-eluting stent era.
MedLine Citation:
PMID:  16008157     Owner:  NLM     Status:  MEDLINE    
Despite recent advances, the in-stent restenosis (ISR) remains a challenging problem in interventional cardiology with an estimated overall restenosis rate of 20%, 25-30% in bare metal stents and 12% in drug-eluting stents (DES). In this review, we provide an overview of therapeutic options which include balloon angioplasty, cutting balloon, debulking techniques, brachytherapy and DES. Intracoronary brachytherapy using beta or gamma radiation had been considered the standard of care for some years. However, the use of DES to treat ISR has been shown to be safe, effective and ease-of-use for the prevention of recurrent restenosis. ISR after DES when focal angiographic pattern is present can be often treated with balloon angioplasty whereas if a non-focal pattern is recognized a new DES implantation is indicated. Waiting for a definitive answer regarding the optimal treatment of ISR from ongoing trials, we present our current approach to ISR.
Patrizia Presbitero; Giacomo Boccuzzi
Related Documents :
11481507 - Impact of pre-stent plaque debulking for chronic coronary total occlusions on restenosi...
16598587 - How to revascularize patients with diabetes mellitus: bypass or stents and drugs?
17572247 - Comparable clinical outcomes with paclitaxel- and sirolimus-eluting stents in unrestric...
11096647 - The efficacy of directional atherectomy prior to stent implantation.
8328187 - The current controversies regarding reperfusion therapy for acute myocardial infarction.
14534067 - Optimal timing of aortic valve replacement for aortic stenosis--are we operating late?
Publication Detail:
Type:  Journal Article; Review    
Journal Detail:
Title:  Italian heart journal : official journal of the Italian Federation of Cardiology     Volume:  6     ISSN:  1129-471X     ISO Abbreviation:  Ital Heart J     Publication Date:  2005 Jun 
Date Detail:
Created Date:  2005-07-12     Completed Date:  2005-10-13     Revised Date:  2005-11-16    
Medline Journal Info:
Nlm Unique ID:  100909716     Medline TA:  Ital Heart J     Country:  Italy    
Other Details:
Languages:  eng     Pagination:  514-21     Citation Subset:  IM    
Department of Invasive Cardiology, Istituto Clinico Humanitas, Rozzano (MI), Italy.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Antineoplastic Agents, Phytogenic / therapeutic use
Blood Vessel Prosthesis Implantation / instrumentation*
Coated Materials, Biocompatible*
Coronary Restenosis / surgery*
Immunosuppressive Agents / therapeutic use
Myocardial Revascularization / methods*
Paclitaxel / therapeutic use
Sirolimus / therapeutic use
Treatment Outcome
Reg. No./Substance:
0/Antineoplastic Agents, Phytogenic; 0/Coated Materials, Biocompatible; 0/Immunosuppressive Agents; 33069-62-4/Paclitaxel; 53123-88-9/Sirolimus

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Revascularization of diabetic patients: are drug-eluting stents the solution?
Next Document:  Prognostic significance of creatine kinase release after percutaneous coronary intervention.